Background/Objectives: Remimazolam, a short-acting benzodiazepine, promotes quick and consistent recovery from anesthesia. However, flumazenil’s rapid antagonistic effects on benzodiazepines during the emergence from anesthesia are thought to increase the risk of postoperative nausea and vomiting (PONV). This study aimed to compare the rate of PONV in monitored anesthesia care (MAC) with remimazolam versus conventional MAC with dexmedetomidine. Methods: This single-center retrospective study included all cases with transcatheter aortic valve replacements (TAVR) performed using MAC at our institution between January 2019 and April 2023. The patients were divided into remimazolam and dexmedetomidine–propofol groups based on the anesthetic method used. We used propensity score matching at a 1:1 ratio to account for the patient backgrounds. The primary outcome measure was the rate of PONV within 48 h. Secondary outcome measures included the severity of PONV and the number of antiemetics administered. Results: This study included 177 subjects. Following propensity score matching, 61 patients were allocated to each group. The incidence of PONV within 48 h after surgery was 4.92% in the remimazolam group and 3.28% in the dexmedetomidine–propofol group, with no significant difference between the two groups (p = 0.817). There was no significant difference between the two groups in terms of the secondary outcomes, including the severity of PONV (p = 0.190) and the use of antiemetics (p = 0.690). Conclusions: In TAVR with MAC and remimazolam, the incidence of PONV within 48 h was comparable to that of dexmedetomidine.
This case report discusses the effective use of spinal cord stimulation (SCS) to treat lower limb pain caused by conus medullaris syndrome. A 49-year-old woman presented with persistent right lower limb pain and numbness following laparoscopic colon resection surgery. During epidural anesthesia, she experienced electric shock-like pain, which continued after surgery. MRI revealed fluid around the T12 thoracic spinal cord, suggesting spinal injury. Despite initial treatments, including epidural and nerve root blocks, the pain persisted. Further intervention with SCS led to significant pain reduction and improved mobility, enabling the patient to engage in rehabilitation. Conus medullaris syndrome, typically involving the T11-T12 to L2 spinal cord levels, can cause varied symptoms, including muscle weakness, atrophy, and radicular pain. In this case, the injury at the T11-T12 level presented with pain localized to the L2-L3 nerve root area, complicating the diagnosis. SCS, known for its efficacy in managing neuropathic pain, proved to be a suitable treatment for this patient, whose pain was refractory to conservative therapies. The treatment led to sustained pain relief and facilitated rehabilitation. This case highlights the diagnostic difficulties associated with conus medullaris syndrome; the symptoms of this condition may be similar to those of other conditions such as spinal pain. In this case, SCS was highly effective in treating neuropathic pain associated with spinal cord injury. In conclusion, SCS therapy provides significant relief for patients with conus medullaris syndrome, underscoring its importance in the management of chronic intractable neuropathic pain.